0000950170-23-034147.txt : 20230724 0000950170-23-034147.hdr.sgml : 20230724 20230724193100 ACCESSION NUMBER: 0000950170-23-034147 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230721 FILED AS OF DATE: 20230724 DATE AS OF CHANGE: 20230724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dworak Leiden CENTRAL INDEX KEY: 0001986012 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 231106127 MAIL ADDRESS: STREET 1: C/O TSCAN THERAPEUTICS, INC. STREET 2: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 3 1 ownership.xml 3 X0206 3 2023-07-21 0 0001783328 TScan Therapeutics, Inc. TCRX 0001986012 Dworak Leiden C/O TSCAN THERAPEUTICS, INC. 830 WINTER STREET WALTHAM MA 02451 false true false false Chief Accounting Officer Voting Common Stock 5692 D Stock Option (Right to Buy) 2.90 2032-04-03 Voting Common Stock 37500 D Stock Option (Right to Buy) 1.81 2033-02-01 Voting Common Stock 28750 D Stock Option (Right to Buy) 2.49 2033-06-12 Voting Common Stock 163800 D The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of April 4, 2022, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of February 2, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. 96,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 67,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023. /s/ Leiden Dworak 2023-07-24